EP1102855A1 - Verfahren zur herstellung von pflanzen mit erhöhtem gehalt an flavonoiden und phenolischen verbindungen - Google Patents
Verfahren zur herstellung von pflanzen mit erhöhtem gehalt an flavonoiden und phenolischen verbindungenInfo
- Publication number
- EP1102855A1 EP1102855A1 EP00945714A EP00945714A EP1102855A1 EP 1102855 A1 EP1102855 A1 EP 1102855A1 EP 00945714 A EP00945714 A EP 00945714A EP 00945714 A EP00945714 A EP 00945714A EP 1102855 A1 EP1102855 A1 EP 1102855A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- plants
- plant
- flavonoids
- activity
- hydroxylase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000002215 flavonoids Chemical class 0.000 title claims abstract description 31
- 229930003935 flavonoid Natural products 0.000 title claims abstract description 30
- 235000017173 flavonoids Nutrition 0.000 title claims abstract description 30
- 230000001965 increasing effect Effects 0.000 title claims abstract description 16
- 238000004519 manufacturing process Methods 0.000 title claims description 12
- 150000002989 phenols Chemical class 0.000 title description 10
- 230000000694 effects Effects 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 24
- 102000004190 Enzymes Human genes 0.000 claims abstract description 15
- 108090000790 Enzymes Proteins 0.000 claims abstract description 15
- 230000002068 genetic effect Effects 0.000 claims abstract description 4
- 241000196324 Embryophyta Species 0.000 claims description 42
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 19
- 230000000692 anti-sense effect Effects 0.000 claims description 16
- 235000013824 polyphenols Nutrition 0.000 claims description 15
- 240000003768 Solanum lycopersicum Species 0.000 claims description 14
- 108010018087 Flavanone 3-dioxygenase Proteins 0.000 claims description 13
- 230000014509 gene expression Effects 0.000 claims description 13
- 244000269722 Thea sinensis Species 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 9
- 235000007688 Lycopersicon esculentum Nutrition 0.000 claims description 8
- 235000013305 food Nutrition 0.000 claims description 8
- 235000013616 tea Nutrition 0.000 claims description 8
- 239000004615 ingredient Substances 0.000 claims description 7
- 238000005728 strengthening Methods 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 238000000855 fermentation Methods 0.000 claims description 4
- 230000004151 fermentation Effects 0.000 claims description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 4
- 235000020971 citrus fruits Nutrition 0.000 claims description 3
- 239000002537 cosmetic Substances 0.000 claims description 3
- 235000015872 dietary supplement Nutrition 0.000 claims description 3
- 230000002255 enzymatic effect Effects 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 244000291564 Allium cepa Species 0.000 claims description 2
- 235000002732 Allium cepa var. cepa Nutrition 0.000 claims description 2
- 240000002234 Allium sativum Species 0.000 claims description 2
- 240000007087 Apium graveolens Species 0.000 claims description 2
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 claims description 2
- 235000010591 Appio Nutrition 0.000 claims description 2
- 240000005662 Aronia melanocarpa Species 0.000 claims description 2
- 235000007425 Aronia melanocarpa Nutrition 0.000 claims description 2
- 235000007319 Avena orientalis Nutrition 0.000 claims description 2
- 244000075850 Avena orientalis Species 0.000 claims description 2
- 241000167854 Bourreria succulenta Species 0.000 claims description 2
- 240000002791 Brassica napus Species 0.000 claims description 2
- 240000007124 Brassica oleracea Species 0.000 claims description 2
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 claims description 2
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 claims description 2
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 claims description 2
- 235000004221 Brassica oleracea var gemmifera Nutrition 0.000 claims description 2
- 235000017647 Brassica oleracea var italica Nutrition 0.000 claims description 2
- 235000012905 Brassica oleracea var viridis Nutrition 0.000 claims description 2
- 240000003259 Brassica oleracea var. botrytis Species 0.000 claims description 2
- 244000178937 Brassica oleracea var. capitata Species 0.000 claims description 2
- 244000308368 Brassica oleracea var. gemmifera Species 0.000 claims description 2
- 235000004977 Brassica sinapistrum Nutrition 0.000 claims description 2
- 235000009467 Carica papaya Nutrition 0.000 claims description 2
- 240000006432 Carica papaya Species 0.000 claims description 2
- 241000207199 Citrus Species 0.000 claims description 2
- 240000000560 Citrus x paradisi Species 0.000 claims description 2
- 240000007154 Coffea arabica Species 0.000 claims description 2
- 235000002767 Daucus carota Nutrition 0.000 claims description 2
- 244000000626 Daucus carota Species 0.000 claims description 2
- 235000016623 Fragaria vesca Nutrition 0.000 claims description 2
- 240000009088 Fragaria x ananassa Species 0.000 claims description 2
- 235000011363 Fragaria x ananassa Nutrition 0.000 claims description 2
- 244000194101 Ginkgo biloba Species 0.000 claims description 2
- 235000010469 Glycine max Nutrition 0.000 claims description 2
- 235000008694 Humulus lupulus Nutrition 0.000 claims description 2
- 244000025221 Humulus lupulus Species 0.000 claims description 2
- 235000010829 Prunus spinosa Nutrition 0.000 claims description 2
- 240000004350 Prunus spinosa Species 0.000 claims description 2
- 241000209056 Secale Species 0.000 claims description 2
- 235000007238 Secale cereale Nutrition 0.000 claims description 2
- 235000009470 Theobroma cacao Nutrition 0.000 claims description 2
- 244000299461 Theobroma cacao Species 0.000 claims description 2
- 235000021307 Triticum Nutrition 0.000 claims description 2
- 244000098338 Triticum aestivum Species 0.000 claims description 2
- 240000000851 Vaccinium corymbosum Species 0.000 claims description 2
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims description 2
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims description 2
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 2
- 240000006365 Vitis vinifera Species 0.000 claims description 2
- 238000010170 biological method Methods 0.000 claims description 2
- 235000021014 blueberries Nutrition 0.000 claims description 2
- 235000019693 cherries Nutrition 0.000 claims description 2
- 235000016213 coffee Nutrition 0.000 claims description 2
- 235000013353 coffee beverage Nutrition 0.000 claims description 2
- 235000004611 garlic Nutrition 0.000 claims description 2
- 235000011197 perejil Nutrition 0.000 claims description 2
- 235000008100 Ginkgo biloba Nutrition 0.000 claims 1
- 240000009164 Petroselinum crispum Species 0.000 claims 1
- 239000012634 fragment Substances 0.000 description 27
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 15
- 239000002299 complementary DNA Substances 0.000 description 15
- 229940088598 enzyme Drugs 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 9
- 230000003078 antioxidant effect Effects 0.000 description 9
- 241000701489 Cauliflower mosaic virus Species 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 239000003963 antioxidant agent Substances 0.000 description 8
- 235000006708 antioxidants Nutrition 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 235000012000 cholesterol Nutrition 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- HLVQZEMFVYGIGH-UHFFFAOYSA-L 4-(1-oxidopropylidene)-3,5-dioxocyclohexane-1-carboxylate Chemical compound CCC([O-])=C1C(=O)CC(C([O-])=O)CC1=O HLVQZEMFVYGIGH-UHFFFAOYSA-L 0.000 description 6
- 235000002560 Solanum lycopersicum Nutrition 0.000 description 6
- 210000003494 hepatocyte Anatomy 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000003923 Protein Kinase C Human genes 0.000 description 5
- 108090000315 Protein Kinase C Proteins 0.000 description 5
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 5
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 5
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 5
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 235000021283 resveratrol Nutrition 0.000 description 5
- 229940016667 resveratrol Drugs 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 4
- 235000005487 catechin Nutrition 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000000378 dietary effect Effects 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- SBHXYTNGIZCORC-UHFFFAOYSA-N eriodyctiol Natural products O1C2=CC(O)=CC(O)=C2C(=O)CC1C1=CC=C(O)C(O)=C1 SBHXYTNGIZCORC-UHFFFAOYSA-N 0.000 description 4
- 229930003944 flavone Natural products 0.000 description 4
- 150000002213 flavones Chemical class 0.000 description 4
- 235000011949 flavones Nutrition 0.000 description 4
- 235000009569 green tea Nutrition 0.000 description 4
- GWCPBEMISACTHQ-AWEZNQCLSA-N luteoliflavan Chemical compound C1([C@@H]2CCC3=C(O)C=C(C=C3O2)O)=CC=C(O)C(O)=C1 GWCPBEMISACTHQ-AWEZNQCLSA-N 0.000 description 4
- GWCPBEMISACTHQ-UHFFFAOYSA-N luteoliflavan Natural products O1C2=CC(O)=CC(O)=C2CCC1C1=CC=C(O)C(O)=C1 GWCPBEMISACTHQ-UHFFFAOYSA-N 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 230000008635 plant growth Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 3
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 108010066133 D-octopine dehydrogenase Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 229930182558 Sterol Natural products 0.000 description 3
- 235000006468 Thea sinensis Nutrition 0.000 description 3
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 3
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229950001002 cianidanol Drugs 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 244000038559 crop plants Species 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 150000008442 polyphenolic compounds Chemical class 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 150000003432 sterols Chemical class 0.000 description 3
- 235000003702 sterols Nutrition 0.000 description 3
- 235000021286 stilbenes Nutrition 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 229930014124 (-)-epigallocatechin gallate Natural products 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- NGSWKAQJJWESNS-UHFFFAOYSA-N 4-coumaric acid Chemical compound OC(=O)C=CC1=CC=C(O)C=C1 NGSWKAQJJWESNS-UHFFFAOYSA-N 0.000 description 2
- AEUAEICGCMSYCQ-UHFFFAOYSA-N 4-n-(7-chloroquinolin-1-ium-4-yl)-1-n,1-n-diethylpentane-1,4-diamine;dihydrogen phosphate Chemical compound OP(O)(O)=O.ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 AEUAEICGCMSYCQ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 2
- HBQJTBXZMPSVBP-UHFFFAOYSA-N Cyanidine Natural products OC1=CC(=C2/Oc3cc(O)cc(O)c3C=C2O)C=CC1=O HBQJTBXZMPSVBP-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 238000004435 EPR spectroscopy Methods 0.000 description 2
- 101150010772 F3H gene Proteins 0.000 description 2
- 239000009429 Ginkgo biloba extract Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 2
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 244000061176 Nicotiana tabacum Species 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 102000038030 PI3Ks Human genes 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- 240000007377 Petunia x hybrida Species 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 2
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 description 2
- 241000219094 Vitaceae Species 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 150000001789 chalcones Chemical class 0.000 description 2
- 235000005513 chalcones Nutrition 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 230000002113 chemopreventative effect Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- VEVZSMAEJFVWIL-UHFFFAOYSA-O cyanidin cation Chemical compound [O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC=C(O)C(O)=C1 VEVZSMAEJFVWIL-UHFFFAOYSA-O 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 2
- 235000001785 ferulic acid Nutrition 0.000 description 2
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 2
- 229940114124 ferulic acid Drugs 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 230000035784 germination Effects 0.000 description 2
- 229940068052 ginkgo biloba extract Drugs 0.000 description 2
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 2
- 235000021021 grapes Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000007954 growth retardant Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 2
- 150000002515 isoflavone derivatives Chemical class 0.000 description 2
- 235000008696 isoflavones Nutrition 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000006870 ms-medium Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- VGEREEWJJVICBM-UHFFFAOYSA-N phloretin Chemical compound C1=CC(O)=CC=C1CCC(=O)C1=C(O)C=C(O)C=C1O VGEREEWJJVICBM-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000000700 radioactive tracer Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- PCMORTLOPMLEFB-ONEGZZNKSA-N sinapic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-ONEGZZNKSA-N 0.000 description 2
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 2
- 239000000021 stimulant Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 2
- RVKCCVTVZORVGD-UHFFFAOYSA-N trinexapac-ethyl Chemical group O=C1CC(C(=O)OCC)CC(=O)C1=C(O)C1CC1 RVKCCVTVZORVGD-UHFFFAOYSA-N 0.000 description 2
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 description 1
- 235000004911 (-)-epigallocatechin gallate Nutrition 0.000 description 1
- FSYDWKPCKNCRDI-OLZOCXBDSA-N (2S,4R)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-2H-chromene-4,5,7-triol Chemical compound O[C@@H]1C[C@H](Oc2cc(O)cc(O)c12)c1ccc(O)c(O)c1 FSYDWKPCKNCRDI-OLZOCXBDSA-N 0.000 description 1
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- ZWTDXYUDJYDHJR-UHFFFAOYSA-N (E)-1-(2,4-dihydroxyphenyl)-3-(2,4-dihydroxyphenyl)-2-propen-1-one Natural products OC1=CC(O)=CC=C1C=CC(=O)C1=CC=C(O)C=C1O ZWTDXYUDJYDHJR-UHFFFAOYSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- HSTZMXCBWJGKHG-UHFFFAOYSA-N (E)-piceid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC(C=CC=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- NGSWKAQJJWESNS-ZZXKWVIFSA-M 4-Hydroxycinnamate Natural products OC1=CC=C(\C=C\C([O-])=O)C=C1 NGSWKAQJJWESNS-ZZXKWVIFSA-M 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- DFYRUELUNQRZTB-UHFFFAOYSA-N Acetovanillone Natural products COC1=CC(C(C)=O)=CC=C1O DFYRUELUNQRZTB-UHFFFAOYSA-N 0.000 description 1
- MDDPZOZWEZNMTK-AWEZNQCLSA-N Apigeniflavan Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2CC1 MDDPZOZWEZNMTK-AWEZNQCLSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- IMXSCCDUAFEIOE-UHFFFAOYSA-N D-Octopin Natural products OC(=O)C(C)NC(C(O)=O)CCCN=C(N)N IMXSCCDUAFEIOE-UHFFFAOYSA-N 0.000 description 1
- IMXSCCDUAFEIOE-RITPCOANSA-N D-octopine Chemical compound [O-]C(=O)[C@@H](C)[NH2+][C@H](C([O-])=O)CCCNC(N)=[NH2+] IMXSCCDUAFEIOE-RITPCOANSA-N 0.000 description 1
- GCPYCNBGGPHOBD-UHFFFAOYSA-N Delphinidin Natural products OC1=Cc2c(O)cc(O)cc2OC1=C3C=C(O)C(=O)C(=C3)O GCPYCNBGGPHOBD-UHFFFAOYSA-N 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 206010054044 Diabetic microangiopathy Diseases 0.000 description 1
- 102000016680 Dioxygenases Human genes 0.000 description 1
- 108010028143 Dioxygenases Proteins 0.000 description 1
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 238000005740 Freeman reaction Methods 0.000 description 1
- 229930191978 Gibberellin Natural products 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 241000764238 Isis Species 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- FSYDWKPCKNCRDI-STQMWFEESA-N Luteoforol Natural products O[C@@H]1c2c(O)cc(O)cc2O[C@H](c2cc(O)c(O)cc2)C1 FSYDWKPCKNCRDI-STQMWFEESA-N 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- MZSGWZGPESCJAN-MOBFUUNNSA-N Melitric acid A Natural products O([C@@H](C(=O)O)Cc1cc(O)c(O)cc1)C(=O)/C=C/c1cc(O)c(O/C(/C(=O)O)=C/c2cc(O)c(O)cc2)cc1 MZSGWZGPESCJAN-MOBFUUNNSA-N 0.000 description 1
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 1
- YQHMWTPYORBCMF-UHFFFAOYSA-N Naringenin chalcone Natural products C1=CC(O)=CC=C1C=CC(=O)C1=C(O)C=C(O)C=C1O YQHMWTPYORBCMF-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- 244000062780 Petroselinum sativum Species 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 241001672648 Vieira Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000001164 bioregulatory effect Effects 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- FFNDMZIBVDSQFI-UHFFFAOYSA-N delphinidin chloride Chemical compound [Cl-].[O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC(O)=C(O)C(O)=C1 FFNDMZIBVDSQFI-UHFFFAOYSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000009101 diabetic angiopathy Diseases 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 1
- VFSWRBJYBQXUTE-UHFFFAOYSA-N epi-Gallocatechin 3-O-gallate Natural products Oc1ccc2C(=O)C(OC(=O)c3cc(O)c(O)c(O)c3)C(Oc2c1)c4cc(O)c(O)c(O)c4 VFSWRBJYBQXUTE-UHFFFAOYSA-N 0.000 description 1
- SBHXYTNGIZCORC-ZDUSSCGKSA-N eriodictyol Chemical compound C1([C@@H]2CC(=O)C3=C(O)C=C(C=C3O2)O)=CC=C(O)C(O)=C1 SBHXYTNGIZCORC-ZDUSSCGKSA-N 0.000 description 1
- TUJPOVKMHCLXEL-UHFFFAOYSA-N eriodictyol Natural products C1C(=O)C2=CC(O)=CC(O)=C2OC1C1=CC=C(O)C(O)=C1 TUJPOVKMHCLXEL-UHFFFAOYSA-N 0.000 description 1
- 235000011797 eriodictyol Nutrition 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 235000019225 fermented tea Nutrition 0.000 description 1
- 229930003949 flavanone Natural products 0.000 description 1
- 150000002208 flavanones Chemical class 0.000 description 1
- 235000011981 flavanones Nutrition 0.000 description 1
- NWKFECICNXDNOQ-UHFFFAOYSA-N flavylium Chemical compound C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=[O+]1 NWKFECICNXDNOQ-UHFFFAOYSA-N 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 239000003448 gibberellin Substances 0.000 description 1
- IXORZMNAPKEEDV-OBDJNFEBSA-N gibberellin A3 Chemical class C([C@@]1(O)C(=C)C[C@@]2(C1)[C@H]1C(O)=O)C[C@H]2[C@]2(C=C[C@@H]3O)[C@H]1[C@]3(C)C(=O)O2 IXORZMNAPKEEDV-OBDJNFEBSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003630 growth substance Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 229930005346 hydroxycinnamic acid Natural products 0.000 description 1
- 235000010359 hydroxycinnamic acids Nutrition 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 238000009160 phytotherapy Methods 0.000 description 1
- 239000005648 plant growth regulator Substances 0.000 description 1
- 235000021135 plant-based food Nutrition 0.000 description 1
- 229960003764 polydatin Drugs 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 235000020095 red wine Nutrition 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 1
- 235000017700 silymarin Nutrition 0.000 description 1
- 229960004245 silymarin Drugs 0.000 description 1
- PCMORTLOPMLEFB-UHFFFAOYSA-N sinapinic acid Natural products COC1=CC(C=CC(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-UHFFFAOYSA-N 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 150000001629 stilbenes Chemical class 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 238000013337 sub-cultivation Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- NGSWKAQJJWESNS-ZZXKWVIFSA-N trans-4-coumaric acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C=C1 NGSWKAQJJWESNS-ZZXKWVIFSA-N 0.000 description 1
- HSTZMXCBWJGKHG-CUYWLFDKSA-N trans-piceid Polymers O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-CUYWLFDKSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 239000000717 tumor promoter Substances 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 235000020097 white wine Nutrition 0.000 description 1
- 235000014101 wine Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
- A01H1/00—Processes for modifying genotypes ; Plants characterised by associated natural traits
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9771—Ginkgophyta, e.g. Ginkgoaceae [Ginkgo family]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
- C12N15/825—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine involving pigment biosynthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/86—Products or compounds obtained by genetic engineering
Definitions
- the present invention relates to a process for increasing the content of flavonoids and phenolic constituents in plants, characterized in that a plant is produced using molecular genetic methods in which the activity of the enzyme flavanon-3-hydroxylase is reduced.
- the method according to the invention is characterized in that the enzyme flavanone-3-hydroxylase by molecular biological methods (eg anti-sense construct, co-suppression, the expression of specific antibodies or the expression of specific inhibitors) in whole or in part, continuously or temporarily activity in the entire plant or in parts of the plant is reduced.
- molecular biological methods eg anti-sense construct, co-suppression, the expression of specific antibodies or the expression of specific inhibitors
- the invention furthermore relates to plants with an increased content of flavonoids and phenolic ingredients, characterized in that their enzymatic activity of the enzyme flavonon-3-hydoxylase is reduced.
- the invention relates to the use of plants - produced by the process according to the invention - or parts of these plants as foods, food supplements or for the preparation of curative, health-promoting or strengthening agents (juices, teas, extracts, fermentation products) for humans and animals and for the manufacture of cosmetics.
- curative, health-promoting or strengthening agents juices, teas, extracts, fermentation products
- phenolic substances are found in plants, eg caffeic acid, ferulic acid, chlorogenic acid, gallic acid, eugenol, lignans, coumarins, lignin, stilbenes (polydatin, resveratrol), flavonoids (flavones, catechins, flavanones, anthocyanidins, isoflavones), polymethoxylated flavones. Accordingly, phenols are also a general component of many plant-based foods and stimulants. Certain phenolic substances are of particular importance because they can exert an antioxidative effect in human or animal metabolism after ingestion with food (Baum, B. 0 .; Perun, AL Antioxidant efficiency versus structure.
- polyphenols have various effects on cell metabolism.
- signal transduction enzymes such as protein kinase C, tyrosine protein kinase and phosphatidylinositol-3-kinase are modulated
- a number of healing, health-promoting or strengthening agents are therefore already obtained from suitable plants, the effect of which is based on their content of phenolic substances (Gerritsen, ME; Carley, WW; Ranges, GE; Shen, CP; Phan, SA; Ligon, GF ; Perry, CA Flavonoids inhibit cyto-kine-induced endothelial cell adhesion protein gene expression.
- the resveratrol (along with other components) contained in white wine, but especially in red wine, is effective, for example, against heart attacks, cardiovascular diseases and cancer (Gehm, BD; McAndrews, JM; Chien, P.-Y .; Jameson, JL Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for estrogen reeeptor.
- polymethoxylated flavones from citrus fruits also have a potential antitumor effect (Chem, J.; Montanari, AM; Widmer, WW Two new polymethoxylated flavones, a class of compounds with potential anticancer activity, isolated from cold pressed dancy tangerine peel oil solids, J Agric Food Chem 45: 364-368, (1997)).
- the object of the present invention was to find a simple and inexpensive method for increasing the content of flavonoids and phenolic constituents in crop plants.
- Acylcyclohexadiones such as Prohexadione-Ca and Trinexapac-ethyl (older name: Cimectacarb) are used as bioregulators to inhibit plant growth. Their bioregulatory effect is due to the fact that they block the bio-synthesis of gibberellins that promote growth. Because of their structural relationship to 2-oxoglutaric acid, they inhibit certain dioxygenases that require 2-0xoglutaric acid as a co-substrate (Rademacher, W, Biochemical effects of plant growth retardants, in: Plant Biochemical Regulators, Gausman, HW (ed.) , Marcel Dekker, Inc., New York, pp. 169-200
- Luteoliflavan is not normally found in apple tissue and eriodyctiol occurs only in small quantities as an intermediate in flavonoid metabolism.
- the expected flavonoids catechin and cyanidine were not detectable in the treated tissue or only occurred in significant amounts.
- PAL phenylalanine ammonium lyase
- the flavonoids eriodictyol, proanthocyanidins which are substituted on the C atom 3 with hydrogen, eg luteoforol, luteoliflavan, apigeniflavan and tricetiflavan, as well as homogeneous and heterogeneous oligomers and polymers increasingly formed from the mentioned and structurally related substances.
- the concentration of the glycosides of the flovonoids, the phenolic compounds, the chalcones and the stilbene is also increased.
- genetically modified crop plants were generated in which the activity of F3H was reduced in whole or in part, permanently or temporarily, by anti-sense constructs, in the entire plant or in individual plant organs or tissues , so that the content of healing, health-promoting or strengthening ingredients was quantitatively and qualitatively improved.
- the process according to the invention for increasing the content of flavonoids and phenolic compounds by expression of the flavonon-3-hydroxylase in an antisense orientation can be carried out successfully in the following crop plants, the process not being limited to the plants mentioned: grapevine, cherry , Tomato, plum, sloe, blueberry, strawberry, citrus (such as orange, grapefruit), papaya, red cabbage, broccoli, Brussels sprouts, cocoa, kale, carrot, parsley, celery, onions, garlic, tea, coffee, hops, soy , Rapeseed, oats, wheat, rye, Aronia melanocarpa, Ginko biloba.
- the invention furthermore relates to plants with an increased content of flavonoids and phenolic constituents produced by the process according to the invention, characterized in that their enzymatic activity of the enzyme flavanon-3-hydroxylase is reduced.
- flavonoids and phenolic constituents produced by the process according to the invention, characterized in that their enzymatic activity of the enzyme flavanon-3-hydroxylase is reduced.
- other molecular genetic methods known from the literature such as co-suppression or the expression of specific antibodies, can also be used to achieve this effect .
- the invention relates to the use of plants - produced by the process according to the invention - or parts of these plants as food, food supplements or for the production of curative, health-promoting or strengthening agents (juices, teas, extracts, fermentation products) for humans and animals and for Manufacture of cosmetics.
- NF-kB redox-sensitive transcription factors
- Ripe tomato fruits from Lycopersicon esculentum Mill.cv. Moneymakers were washed, dried and the pericarp was freed from seeds, middle columnella and wooden parts using a sterile blade.
- the pericarp (approx. 50 g) was frozen in liquid nitrogen. The material was then crushed in a mixer. The comminuted material was mixed with 100 ml homogenizing medium in a pre-cooled mortar. The suspension was then transferred to centrifuge cups by pressing through sterile gauze cloths. Then 1/10 vol 10% SDS was added and mixed well. After 10 minutes on ice, 1 volume of phenol / chloroform was added, the centrifuge cup closed and mixed well.
- the supernatant was transferred to a new reaction vessel. This was followed by three further phenol / chloroform extractions and one chloroform extraction. In the following, 1 vol 3 M NaAC and 2.5 vol ethanol were added. The nucleic acids were precipitated overnight at -20 ° C. The next morning, the nucleic acids were pelleted for 15 minutes at 10,000 rpm in the refrigerated centrifuge (4 ° C). The supernatant was discarded and the pellet resuspended in 5 ml of cold 3 M NaAc. This washing step was repeated twice. The pellet was washed with 80% ethanol. The completely dried pellet was taken up in about 0.5 ml of sterile DEPC water and the RNA concentration was determined photometrically.
- RNA 20 ⁇ g of total RNA were first mixed with 3.3 ⁇ l of 3M sodium acetate solution, 2 ⁇ l of IM magnesium sulfate solution and made up to 100 ⁇ l of final volume with DEPC water.
- a microliter RNase-free DNase (Boehringer Mannheim) was added and incubated at 37 ° for 45 min. After removing the enzyme by shaking with phenol / chloroform / isoamyl alcohol, the RNA was precipitated with ethanol and the pellet was taken up in 100 ⁇ l DEPC water. 2.5 ⁇ g RNA from this solution were transcribed into cDNA using a cDNA kit (Gibco BRL).
- sequence of the oligonucleotide derived using the peptide sequence DHQAW was as follows: 5'-CTT CAC ACA (C / G / T) GC (C / T) TG (A / G) TG (A / G) TC-3.
- the PCR reaction was carried out using the Perkin-Elmer tTth polymerase according to the manufacturer's instructions. 1/8 of the cDNA was used as template (corresponds to 0.3 ⁇ g RNA).
- the PCR program was:
- the fragment was cloned into Promega's vector pGEM-T according to the manufacturer's instructions.
- the correctness of the fragment was checked by sequencing.
- the PCR fragment was isolated using the restriction sites Ncol and Pstl present in the polylinker of the vector pGEM-T and the protruding ends were blunt-ended using the T4 polymerase. This fragment
- Fragment A (529 bp) contains the 35S promoter of the CaMV (nucleotides 6909 to 7437 of the cauliflower mosaic virus).
- Fragment B the fragment of the F3H gene in antisense orientation.
- Fragment C (192 bp) contains the termination signal of the octopine synthase gene. Cloning of a larger cDNA fragment of Flavanone-3-hydroxylase from Lycopersicon esculentum Mill.cv. Moneymaker using the 5'RACE system.
- a second antisense construct should be generated using a larger F3H fragment.
- the 5'RACE method (System for Rapid amplification of cDNA ends) was used to clone a larger fragment of the F3H.
- the cDNA first strand synthesis was carried out according to the manufacturer's instructions using the GSP-1 (gene-specific primer) 5'-TTCAC-CACTGCCTGGTGGTCC-3 '. Following an RNase digest, the cDNA was purified using the GlassMAX spin system from Life Tecgnologies TM in accordance with the manufacturer's instructions.
- a cytosine homopolymer was added to the 3 'end of the purified single-stranded F3H cDNA using the terminal deoxynucleotydil transferase according to the manufacturer's instructions.
- the 5 'extended F3H cDNA was amplified using a second gene-specific primer (GSP-2) which binds in the region 3' before the GSP-1 recognition sequence and thus enables a "nested” PCR.
- GSP-2 second gene-specific primer
- the 5 'primer was that of Manufacturer supplied "5 'RACE abrided anchor primer", which is complementary to the homopolymeric dC tail of the cDNA.
- the cDNA fragment amplified in this way and designated as FSH extended was cloned into the vector pGEM-T from Promega according to the manufacturer's instructions.
- the identity of the cDNA was confirmed by sequencing.
- the FSHextended cDNA fragment was isolated using the restriction sites Ncol and Pstl present in the polylinker of the vector pGEM-T and the protruding ends under Conversion using T4 polymerase and blunt ends.
- This fragment was cloned into a Smal (blunt) cut vector pBinAR (Höfgen and Willmitzer, 1990) (see Figure 3).
- This vector mediates resistance to the antibiotic kanamycin in plants.
- the DNA constructs obtained contained the PCR fragment in sense and antisense orientation. The antisense construct was used to generate transgenic plants.
- Fragment A (529 bp) contains the 35S promoter of the CaMV (nucleotides 6909 to 7437 of the cauliflower mosaic virus).
- Fragment B the fragment of the F3H gene in antisense orientation.
- Fragment C (192 bp) contains the termination signal of the octopine synthesis gene.
- Tomato seeds (Lycopersicon esculentum Mill. Cv. Moneymaker) were incubated by 10 minutes incubation in 4% sodium hypochlorite solution, then washed 3-4 times with sterile distilled water and placed on MS medium with 3% sucrose, pH 6, 1 for germination . After a germination period of 7-10 d, the cotyledons could be used for the transformation.
- Day 2 Sterile filter paper was placed on the plates coated with the tobacco suspension culture without air bubbles. The cross-cut cotyledons were placed on top with the top down. The petri dishes were incubated for 3 days in the culture room.
- Day 5 The agrobacterial culture (LBA4404) was sedimented by centrifugation at approx. 3000 g for 10 min and resuspended in MS medium so that the OD was 0.3. The cotyledon fragments were added to this suspension, which were incubated with gentle shaking for 30 minutes at room temperature. The cotyledon fragments were then dried off somewhat on sterile filter paper and placed back on their starting plates for the continued cultivation for 3 days in the culture room.
- Example 2 in addition a partial fragment of flavanone-3-hydroxylase in antisense orientation, an amount between 10 and 20 mg was weighed exactly and so much DMSO was added that a stock solution of 10 mM total flavonoids was formed. Dilutions of these stock solutions were made in the culture medium immediately before the start of the test. The dilutions were made in 10 steps between 10 -4 and 10 " 8 M.
- the hepatocyte cultures were held for a total of 22 h to demonstrate that cholesterol biosynthesis was influenced by test substances A and B. It was then incubated with serum-free Williams Medium E with the addition of 14 C acetate (only tracer amounts) with the test substances in the stated concentrations for 2 h. A control was carried out for each test series. The methodology is described in detail in Gebhardt (1991) and Gebhardt, Lipids 28: 613 -619 (1993). The tracer amounts of 14 C-acetate quickly exchange with the intracellular acetyl-CoA pool and therefore enable a trouble-free determination of the incorporation of 1 C-acetate in the sterol fraction, which consists of> 90% cholesterol (Gebhardt, 1993).
- Samples A) from the non-genetically modified tomatoes showed no effects on cholesterol biosynthesis.
- cholesterol synthesis was significantly inhibited by samples B from the tomatoes containing a partial fragment of flavanone 3-hydroxylase in the antisense orientation.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Birds (AREA)
- Nutrition Science (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
Abstract
Verfahren zur Erhöhung des Flavonoid-Gehalts in Pflanzen, dadurch gekennzeichnet, dass mit molekulargenetischen Methoden eine Pflanze hergestellt wird, in der die Aktivität des Enzyms Flavanon-3-hydroxylase reduziert ist.
Description
Verfahren zur Herstellung von Pflanzen mit erhöhtem Gehalt an Flavonoiden und phenolischen Verbindungen
Beschreibung
Gegenstand der vorliegenden Erfindung ist ein Verfahren zur Erhöhung des Gehalts an Flavonoiden und phenolischen Inhaltsstoffen in Pflanzen dadurch gekennzeichnet, daß mit molekulargenetischen Methoden eine Pflanze hergestellt wird in der die Aktivität des Enzyms Flavanon-3-hydroxylase reduziert ist.
Desweiteren ist das erfindungsgemäße Verfahren dadurch gekennzeichnet, daß das Enzym Flavanon-3-hydroxylase durch molekular- biologische Verfahren (z.B. Anti-Sense-Konstrukt, Co-Suppression, der Expression spezifischer Antikörper oder der Expression spezifischer Inhibitoren) ganz oder teilweise, andauernd oder vorübergehend, in der gesamten Pflanze oder in Teilen der Pflanze in seiner Aktivität reduziert ist.
Weiterer Gegenstand der Erfindung sind Pflanzen mit erhöhtem Gehalt an Flavonoiden und phenolischen Inhaltsstoffen dadurch gekennzeichnet, daß deren enzymatische Aktivität des Enzyms Flava- non-3-hydoxylase reduziert ist.
Darüberhinaus ist Gegenstand der Erfindung die Verwendung von Pflanzen - hergestellt nach dem erfindungsgemäßen Verfahren - oder von Teilen dieser Pflanzen als Nahrungsmittel, Nahrungser- gänzungsmittel oder zur Herstellung von heilenden, gesundheits- fördernden oder stärkenden Mitteln (Säfte, Tees, Extrakte, Fermentationsprodukte) für Mensch und Tier sowie zur Herstellung von Kosmetika.
Verschiedene phenolische Substanzen kommen in Pflanzen vor, z.B. Kaffeesäure, Ferulasäure, Chlorogensäure, Gallussäure, Eugenol , Lignane, Cumarine, Lignin, Stilbene (Polydatin, Resveratrol) , Flavonoide (Flavone, Catechine, Flavanone, Anthocyanidine, Iso- flavone) , polymethoxylierte Flavone. Demgemäß sind Phenole auch genereller Bestandteil vieler pflanzlicher Nahrungs- und Genuß - mittel. Bestimmte phenolische Substanzen sind von besonderer Bedeutung, da sie nach Aufnahme mit der Nahrung im menschlichen oder tierischen Stoffwechsel eine antioxidative Wirkung ausüben können (Baum, B. 0.; Perun, A. L. Antioxidant efficiency versus structure. Soc. Plast . Engrs Trans 2: 250-257, (1962); Gardner, P.T.; McPhail, D.B. ; Duthie, G.G. Electron spin resonance spectroscopic assessment of the antioxidant potential of teas in aqueous and organic media . J. Sei . Food Agric. 76: 257-262,
(1997); Rice-Evans, C. A. ; Miller, N. J. ; Pananga, G. Structure- antioxidant activity relationship of flavonoids and phenolic acids. Free Radio . Biol . Med. 20: 933-956, (1996); Salah, N. ; Miller, N. J.; Paganga, G.; Tijburg, L. ; Bolwell, G. P. ; Rice- Evans, C. Polyphenolic flavonoids as scavenger of aqueous phase radicals and as chain-breaking antioxidants . Arch Biochem Biophys 322: 339-346, (1995); Stryer, L. Biochemis try S . Francisco: Free- man, (1975); Vieira, 0.; Escargueil-Blanc, I.; Meilhac, 0.; Ba- sile, J. P.; Laranjinha, J.; Almeida, L.; Salvayre, R. ; Negre- Salvayre, A. Effect of dietary phenolic compounds on apoptosis of human cultured endothelial cells induced by oxidized LDL. Br J Pharmacol 123: 565-573, (1998)). Darüber hinaus haben Polyphenole vielfältige Wirkungen auf den Zellstoffwechsel. Unter anderem werden Enzyme der Signaltransduction wie Proteinkinase C, Tyro- sin-Proteinkinase und Phosphatidylinositol-3-kinase moduliert
(Agullo, G. ; Gamet-payrastre, L.,- Manenti, S.; Viala, C; Remesy, C.; Chap, H.; Payrastre, B. Relationship between flavonoid struc- ture and inhibition of phosphatidylinositol 3-kinase: a compari- son with tyrosine kinase and protein kinase C inhibition. Biochem Pharmacol 53 :1649-1657, (1997); Ferriola, P. C; Cody, V.; Mid- dleton, E. Protein kinase C inhibition by plant flavonoids. Kine- tic mechanisms and structure activity relationship. Biochem Pharmacol 38: 1617-1624, (1989); Cushman, M. ; Nagarathman, D.; Burg, D. L.; Geahlen, R. L. Synthesis and protein-tyrosine kinase inhibitory activity of flavonoids analogues. J Λfeed Chem 34:
798-806, (1991); Hagiwara, M. ; Inoue, S.; Tanaka, T.; Nunoki, K. ; Ito, M. ; Hidaka, H. Differential effects of flavonoids as inhibitors of tyrosine protein kinases and serine/threonin protein kinases. Biochem Pharmacol 37: 2987-2992, (1988)), die in- duzierbare NO-Synthase downreguliert (Kobuchi, H.; Droy- efaix, M. T. ,- Christen, Y. ; Packer, L. Ginkgo biloba extract (EGb761) : inhibitory effect on nitric oxide production in the macrophage cell line RAW 264.7. Biochem Pharmacol 53: 897-903, (1997)) und die Genexpression von z. B. Interleukinen und Adhäsionsmolekülen (ICAM-1, VCAM-1) reguliert (Kobuchi, H. ; Droy-Lefaix, M. T.;
Christen, Y.,- Packer, L. Ginkgo biloba extract (EGb761) : inhibitory effect on nitric oxide production in the macrophage cell line RAW 264.7. Biochem Pharmacol 53:897-903, (1997); Wolle, J.; Hill, R. R.; Ferguson, E. ; Devall, L. J.; Trivedi, B. K. ; Newton, R. S. ; Saxena, U. Selective inhibition of Tumor necrosis Factor- induced vascular cell adhesion molecule-1 gene expression by a novel flavonoid. Lack of effect on trascriptional factor NF-kB. Atherioscler Thromb Vase Biol 16: 1501-1508, (1996)). Es gilt als gesichert, daß diese Wirkungen positiv sind zur Vorbeugung und Prävention von Infarkten, Herz-Kreislauferkrankungen, Diabetes, bestimmter verschiedener Krebsarten, Tumorarten und weiterer chronischer Krankheiten (Bertuglia, S.; Malandrino, S.; Colan-
tuoni, A. Effects of the natural flavonoid delphinidin on diabe- tic microangiopathy. Arznei -Forsch/Drug Res 45 : 481 -485, (1995); Griffiths, K. ; Adlercreutz, H.; Boyle, P.; Denis, L.; Nicholson, R.I.; Morton, M.S. Nutri tion and Cancer Oxford: Isis Medical Media, (1996); Hertog, M. G. L.; Fesrens, E. J. M.; Hollman, P. C. K. ; Katan, M. B.; Kromhout, D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen eiderly study. The Lance t 342: 1007-1011, (1993); Kapiotis, S.; Hermann, M. ; Held, I.; Seelos, C. ; Ehringer, H. ,- Gmeiner, B. M. Genistein, the dietary-derived angiogenesis inhibitor, prevents LDL oxidation and protects endothelial cells from damage by atherogenic LDL. Arterioscler Thromb Vase Biol 17: 2868-74, (1997); Stampfer, M. J.; Hennekens, C. H. ; Manson, J. E.; Colditz, G. A. ; Rosner, B.; Willet, W. C. Vitamin E consumption and the risk of coronary di- sease in women. New Engl J Med 328 :1444-1449, (1993); Tijburg, L. B. M.; Mattern, T.; Folts, J. D. ; Weisgerber, U. M.; Katan, M. B. Tea flavonoids and cardiovascular diseases: a review. Crit Rev Food Sei Nutr 37: 771-785, (1997); Kirk, E. A.; Sutherland, P.; Wang, S. A.; Chait, A. ; LeBoeuf, R. C. Dietary isoflavones reduce plasma cholesterol and atherosclerosis in C57BL/6 mice but not LDL reeeptor-deficient mice. J Nutr 128: 954-9, (1998) - Zitate - ) . Aus geeigneten Pflanzen wird daher bereits eine Reihe von heilenden, gesundheitsfördernden oder stärkenden Mitteln gewonnen, deren Wirkung auf ihrem Gehalt an phenolischen Substanzen beruht (Gerritsen, M. E.; Carley, W. W.; Ranges, G. E.; Shen, C. P.; Phan, S. A. ; Ligon, G. F.; Perry, C. A. Flavonoids inhibit cyto- kine-induced endothelial cell adhesion protein gene expression. Am J Pathol 147: 278-292, (1995); Lin, J. K. ; Chen, Y. C. ; Huang, Y. T. ; Lin-Shiau, S. Y. Suppression of protein kinase C and nu- clear oncogene expression as possible molecular mechanisms of cancer chemoprevention by apigenin and curcumin. J Cell Biochem Suppl 28-29:39-48, 1997; Zi, X.; Mukhtar, H. ; Agarval, R. Novel cancer chemoprevenetive effects of a flavonoid antioxidant silymarin: inhibition of mRNA expression of an endogenous tumor promoter TNF alpha. Bioche-τι Biophys Res Comm 239:334-339, 1997. Bekannt ist weiterhin, daß bestimmte pflanzliche Nahrungsmittel oder aus ihnen hergestellte Genußmittel eine positive Wirkung gegen verschiedene Krankheiten ausüben. Das in Weißwein, besonders aber in Rotwein, enthaltene Resveratrol (nebst weiterer Komponen- ten) wirkt beispielsweise gegen Infarkte kardiovasculäre Erkrankungen und Krebs (Gehm, B.D.; McAndrews, J.M.; Chien, P.-Y.; Ja- meson, J.L. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for estrogen reeeptor. Proc Natl Acad Sei USA 94: 14138-14143, (1997),- Jang, M.; Cai , L.; Udeani, G.O.; Slowing, K.V. ; Thomas, C.F.; Beecher, C.W.W. ; Fong, H.H.S; Farns - worth, N.R.; Kinghorn, A.D.; Mehtha, R.G.; Moon, R.C., Pezzuto, J.M. Cancer chemopreventive activity of resveratrol, a natural
product derived from grapes. Sci ence 275: 218-220, (1997). Eine ähnliche Wirkung weisen auch Substanzen wie Catechin, Epicatec- hin-3-gallat, Epigallocatechin und Epigallocatechin-3-gallat auf, die in Blättern von Tee ( Camellia sinensis) vorkommen. Ins- besondere aus nicht-fermentierten Teeblättern (Grüner Tee) hergestellte Getränke sind von positiver gesundheitlicher Relevanz (Hu, G. ; Han, C. ; Chen, J. Inhibition of oncogene expression by green tea and (-) -epigallocatechin gallate in mice. JVutr Cancer 24: 203-209; (1995); Scholz, E; Bertram, B. Camellia sinensis (L.) 0. Kuntze. Der Teestrauch. Z. Phytotherapie 17: 235-250 ,
(1995); Yu, R. ; Jiao, J. J. ; Duh, J. L.; Gudehithlu, K.; Tan, T. H. ; Kong, A. N. Activation of mitogen-activated protein kinases by green tea polyphenols: potential signaling pathways in the re- gulation of antioxidant responsive elements-mediated phase II en- zyme gene expression. Carcinigenesis 18: 451-456, (1997); Jankun, J. ; Selman, S.H.; Swiercz, R. Why drinking green tea could pre- vent cancer. iVature 387: 561, (1997). Darüber hinaus weisen auch polymethoxylierte Flavone aus Zitrusfrüchten eine potentielle an- titumorale Wirkung auf (Chem, J. ; Montanari, A.M. ; Widmer, W.W. Two new polymethoxylierte flavone, a class of compounds with potential anticancer activity, isolated from cold pressed dancy tangerine peel oil solids. J Agric Food Chem 45: 364-368, (1997) ) .
Aufgabe der vorliegenden Erfindung war es, ein einfaches und kostengünstiges Verfahren zur Erhöhung des Gehaltes an Flavonoiden und phenolischen Inhaltsstoffen in Kulturpflanzen zu finden.
Ausgehend von physiologischen Untersuchungen mit Wachstums - regulatoren aus der Gruppe der Acylcyclohexadione wurden nun überraschend gentechnologische Verfahren verfügbar, mit deren Hilfe sich Pflanzen erzeugen lassen, die sich durch einen erhöhten Gehalt an heilenden, gesundheitsfördernden oder stärkenden Inhaltsstoffen ausweisen.
Acylcyclohexadione wie Prohexadion-Ca und Trinexapac-ethyl (ältere Bezeichnung: Cimectacarb) werden als Bioregulatoren zur Hemmung des pflanzlichen Längenwachstums eingesetzt. Ihre bioregu- latorische Wirkung kommt dadurch zustande, daß sie die Bio- Synthese von längenwachstumsfördernden Gibberellinen blockieren. Dabei hemmen sie aufgrund ihrer strukturellen Verwandtschaft zu 2-Oxoglutarsäure bestimmte Dioxygenasen, die 2-0xoglutarsäure als Co-Substrat benötigen (Rademacher, W, Biochemical effects of plant growth retardants, in: Plant Biochemical Regulators, Gaus- man, HW (ed.), Marcel Dekker, Inc., New York, pp. 169-200
(1991) ) . Es ist bekannt, daß derartige Verbindungen auch in den Stoffwechsel von Phenolen eingreifen und so bei mehreren Pflan-
zenarten eine Hemmung der Anthocyanbildung bewirken können (Rade- macher, W et al . , The mode of action of acylcyclohexanediones - a new type of growth retardant, in: Progress in Plant Growth Regulation, Karssen, CM, van Loon, LC, Vreugdenhil, D (eds.), Kluwer 5 Academic Publishers, Dordrecht (1992)). Derartige Effekte auf den Haushalt phenolischer Inhaltsstoffe werden als ursächlich für die Nebenwirkung von Prohexadion-Ca gegen Feuerbrand angegeben (Rade- macher, W et al., Prohexadione-Ca - a new plant growth regulator for apple with interesting biochemical features, Poster auf dem
10 25th Annual Meeting of the Plant Growth Regulation Society of America, 7.-10. Juli 1998, Chicago). A. Lux-Endrich (Dissertation Technische Universität München in Weihenstephan, 1998) findet im Verlauf ihrer Untersuchungen zum Wirkmechanismus von Prohexadion- Ca gegen Feuerbrand, daß es in Zellkulturen von Apfel durch Pro-
15 hexadion-Ca zu einer mehrfachen Erhöhung des Gehaltes an phenolischen Substanzen kommt und daß dabei eine Reihe von sonst nicht .vorhandenen Phenolen auftritt. Im Rahmen dieser Untersuchungen wurde weiterhin gefunden, daß unter dem Einfluß von Prohexadion-Ca relativ hohe Mengen von Luteoliflavan und Eriodyctiol
20 in Sproßgewebe von Apfel auftreten. Luteoliflavan kommt in Apfel - gewebe normalerweise nicht vor und Eriodyctiol tritt als Inter- mediat des Flavonoidstoffwechsels nur in geringen Mengen auf. Die zu erwartenden Flavonoide Catechin und Cyanidin waren im behandelten Gewebe jedoch nicht nachweisbar oder traten nur in deut-
25 lieh reduzierten Mengen auf (S. Römmelt et al, Vortrag 8th International Work- Shop on Fire Blight, Kusadasi, Türkei, 12.-15. Oktober 1998) .
Es kann als gesichert gelten, daß Prohexadion-Ca, Trinexapac-
30 ethyl und andere Acylcyclohexadione 2-Oxoglutarsäure-abhängige Hydroxylasen inhibieren, die im Stoffwechsel phenolischer Substanzen von Bedeutung sind. Dabei handelt es sich primär um Chal - consynthetase (CHS) und um Flavanon-3-hydroxylase (F3H) (W. Heller und G. Forkmann, Biosynthesis, in: The Flavonoids, Har-
35 borne, JB (ed.), Chapman and Hall, New York, 1988). Es kann jedoch nicht ausgeschlossen werden, daß Acylcyclohexadione auch weitere, bislang unbekannte, 2-Oxoglutarsäure-abhängige Hydroxylasen hemmen. Es dürfte ferner naheliegend sein, daß ein Mangel an Catechin, Cyanidin oder anderen Endprodukten der Flavonoid- 0 synthese von der Pflanze registriert wird und daß über einen
Feedback-Mechanismus die Aktivität des Schlüsselenzyms Phenylala- ninammoniumlyase (PAL) erhöht wird. Durch die weiterhin existierende Hemmung von CHS und F3H können diese Flavonoid-Endprodukte jedoch nicht gebildet werden, und es kommt zu einer vermehrten 5 Bildung von Luteoliflavan, Eriodyctiol und anderer Phenole (Abb .1 ) .
Durch die Reduktion der Enzymaktivität des Enzyms Flavanon-3-hy- droxylase (F3H) werden die Flavonoide Eriodictyol, Proanthocyani - dine, die am C-Atom 3 mit Wasserstoff substituiert sind, z.B. Lu- teoforol, Luteoliflavan, Apigeniflavan und Tricetiflavan, sowie homogene und heterogene Oligomere und Polymere aus den genannten und strukturell verwandten Substanzen vermehrt gebildet.
Erhöhte Konzentratonen der Phenole Hydroxyzimtsäure (p-Cumar- säure, Ferulasäure, Sinapinsäure) , Salicylsäure oder Umbellife- ron, einschließlich der aus ihnen gebildeten homogenen und heterogenen Oligomere und Polymere werden nach Reduktion der Enzymaktivität des Enzyms Flavanon-3-hydroxylase (F3H) in Pflanzen festgestellt. Ebenso erhöht sich die Konzentration der Chalcone, wie z.B. Phloretin, und der Stilbene, wie z.B. Resveratrol.
Durch Reduktion der Enzymaktivität des Enzyms Flavanon-3 -hydroxylase wird auch die Konzentration der Glykoside der Flovonoide, der phenolischen Verbindungen, der Chalcone und der Stilbene erhöht.
Ausgehend von diesen Befunden und den daraus abgeleiteten Hypothesen wurden gentechnisch veränderte Kulturpflanzen erzeugt, in denen F3H durch Anti-Sense-Konstrukte ganz oder teilweise, dauerhaft oder vorübergehend, in der gesamten Pflanze oder in einzel- nen Pflanzenorganen oder -geweben in ihren Aktivitäten reduziert war, so daß hier der Gehalt an heilenden, gesundheitsfördernden oder stärkenden Inhaltsstoffen quantitativ und qualitativ verbessert war.
Das erfindungsgemäße Verfahren zur Erhöhung des Gehalts an Flavonoiden und phenolischen Verbindungen durch Expression der Flava- non-3-hydroxylase in Antisens -Orientierung kann erfolgreich bei folgenden Kulturpflanzen ausgeübt werden, wobei das Verfahren nicht auf die genannten Pflanzen beschränkt ist: Weinrebe, Kir- sehe, Tomate, Pflaume, Schlehe, Blaubeere, Erdbeere, Zitrus- früchte (wie Orange, Grapefruit), Papaya, Rotkohl, Broccoli, Rosenkohl, Kakao, Grünkohl, Karotte, Petersilie, Sellerie, Zwiebeln, Knoblauch, Tee, Kaffee, Hopfen, Soja, Raps, Hafer, Weizen, Roggen, Aronia melanocarpa, Ginko biloba.
Gegenstand der Erfindung sind darüberhinaus Pflanzen mit erhöhtem Gehalt an Flavonoiden und phenolischen Inhaltsstoffen hergestellt nach dem erfindungsgemäßen Verfahren dadurch gekennzeichnet, daß deren enzymatische Aktivität des Enzyms Flavanon-3 -hydroxylase reduziert ist.
Alternativ zur Herstellung von Pflanzen, die mit Hilfe der Anti- sense- Technologie in ihrer Flavanon-3 -hydroxylase Aktivität reduziert sind, lassen sich auch andere literaturbekannte molekulargenetische Methoden wie Co-Suppression oder die Expression von spezifischen Antikörpern verwenden, um diesen Effekt zu erreichen.
Darüberhinaus ist Gegenstand der Erfindung die Verwendung von Pflanzen - hergestellt nach dem erfindungsgemäßen Verfahren - oder von Teilen dieser Pflanzen als Nahrungsmittel, Nahrungsmittelergänzungsmittel oder zur Herstellung von heilenden, gesundheitsfördernden oder stärkenden Mitteln (Säfte, Tees, Extrakte, Fermentationsprodukte) für Mensch und Tier sowie zur Herstellung von Kosmetika.
Es wurde nun überraschend gefunden, daß unter dem Einfluß von erfindungsgemäß produzierten Pflanzen oder von Teilen dieser Pflanzen oder aus ihnen hergestellter Produkte (Tees, Extrakte, Fermentationsprodukte, Säfte etc.)
(1) die Antioxidative Kapazität in vi tro (Electron Spin Resonance (ESR) , LDL-Oxidation, Total Antioxidant Capacity, NO-Scaven- ging) verbessert wird;
(2) eine modulierende Wirkung auf Enzyme, vor allem Enzyme der Signal transduktion (Proteinkinase C, Tyrosin-Proteinkinase, Phosphatidylinositoi-3-Kinase) auftritt;
(3) eine Modulation redoxsensitiver Transkriptionsfaktoren (NF- kB, AP-1) in Endothelzellen, Lymphocyten und glatten Muskel - zellen induziert wird;
(4) die Regulation der Genexpression von Targetgenen involviert in die Pathogenese inflammatorischer Erkrankungen (Cytokine IL-1 und IL-8, macrophage chemoattractant protein 1 (MCP-1) , Adhesionsfaktoren ICAM-1 und VCAM-1) moduliert wird;
(5) eine antiaggregatorische Wirkung induziert wird;
(6) die Cholesterinsynthese in Hepatocyten gehemmt wird;
(7) antiproliferative/antineoplastische Effekte bestehen.
Beispi el 1
Klonierung des Gens einer Flavanone-3-Hydroxylase aus Lycopersicon esculentum Mill.cv. Moneymaker.
Reife Tomatenfrüchte von Lycopersicon esculentum Mill.cv. Moneymaker wurden gewaschen, getrocknet und mittels einer sterilen Klinge das Perikarp von Samen, mittlere Kolumnella und Holzteilen befreit. Das Perikarp (ca. 50 g) wurde in fluessigem Stickstoff eingefroren. Das Material wurde anschliessend in einem Mixer zerkleinert. Das zerkleinerte Material wurde in einem vorgekühlten Mörser mit 100 ml Homogenisierungs-Medium versetzt und gemischt. Die Suspension wurde dann in Zentrifugenbecher überführt, indem sie durch sterile Mulltücher gepreßt wurde. Anschließend wurde 1/10 Vol 10% SDS hinzugefügt und gut gemischt. Nach 10 Minuten auf Eis, wurde 1 Vol Phenol/Chloroform zugegeben, der Zentrifugenbecher verschlossen und gut gemischt. Nach 15 inütiger Zentrifugation bei 4000 rpm wurde der Überstand in ein neues Reaktionsgefäß überführt. Es schlössen sich drei weitere Phenol/ Chloroform Extraktionen und eine Chloroform Extraktion an. Im folgenden wurde 1 Vol 3 M NaAC und 2.5 Vol Ethanol zugegeben. Die Fällung der Nukleinsäuren erfolgte über Nacht bei -20°C. Am nächsten Morgen wurden die Nukleinsäuren für 15 Minuten bei 10000 rpm in der Kühlzentrifuge (4°C) pelletiert. Der Überstand wurde ver- worfen und das Pellet in 5-lo ml kaltem 3 M NaAc resuspendiert. Dieser Waschschritt wurde zweimal wiederholt. Das Pellet wurde mit 80%igem Ethanol gewaschen. Das vollständig getrocknet Pellet wurde in ca. 0,5 ml sterilem DEPC Wasser aufgenommen und die RNA- Konzentration photometrisch bestimmt.
20 μg gesamt RNA wurden zunächst mit 3,3 μl 3M Natriumacetat-Lö- sung, 2 μl IM Magnesiumsulfat-Lösung versetzt und auf 100 μl Endvolumen mit DEPC Wasser aufgefüllt. Dazu wurde ein Microliter Rnase freie Dnase (Boehringer Mannheim) gegeben und 45 min bei 37° Grad inkubiert. Nach Entfernen des Enzyms durch ausschütteln mit Phenol/Chloroform/Isoamylalkohol wurde die RNA mit Ethanol gefällt und das Pellet in 100 μl DEPC Wasser aufgenommen. 2 , 5 μg RNA aus dieser Lösung wurden mittels eines cDNA-Kits (Gibco BRL) in cDNA umgeschrieben.
Unter Verwendung von Aminosäuresequenzen die aus für Flava- none-3-Hydroxylase kodierenden cDNA Klonen abgeleitet wurden, konnten konservierte Bereiche in der Primärsequenz identifiziert werden (Britsch et al., Eur. J. Biochem. 217, 745 -754 (1993), die als Grundlage für das Design von degenerierten PCR Oligo- nukleotiden dienten. Das 5' Oligonukleotid wurde unter Verwendung der Peptidsequenz SRWPDK (Aminosäure 147-152 in der Sequenz FL3H
PETHY aus Petunia ybrida ermittelt und hatte f olgende Se quenz :
5 ' -TCI (A/C) G (A/G) TGG CC (A/C/G) GA (C/T) AA (A/G) CC-3 .
Die Sequenz des unter Verwendung der Peptidsequenz DHQAW (Aminosäure 276281 in der Sequenz FL3H PETHY aus Petunia hybridaj abgeleiteten Oligonukleotides lautete wie folgt: 5'-CTT CAC ACA (C/ G/T) GC (C/T) TG (A/G) TG (A/G)TC-3.
10
Die PCR-Reaktion wurde unter Verwendung der tTth-Polymerase von Perkin-Elmer nach Herstellerangaben durchgeführt. Als Template wurden 1/8 der cDNA eingesetzt (entspricht 0,3 μg RNA). Das PCR- Programm lautete:
15
30 Zyklen
94 Grad 4 sec
40 Grad 30 sec
72 Grad 2 min
20 72 Grad 10 min
Das Fragment wurde nach Herstellerangaben in den Vektor pGEM-T von Promega kloniert.
25 Die Richtigkeit des Fragmentes wurde durch Sequenzierung überprüft. Das PCR Fragment wurde unter Verwendung der im Polylinker des Vektors pGEM-T vorhandenen Restriktionsschnittstellen Ncol und Pstl isoliert und die überstehenden Enden unter Verwendung der T4-Polymerase in glatte Enden überführt. Dieses Fragment
30 wurde in einen Smal (blunt) geschnittenen Vektor pBinAR (Höfgen und Willmitzer, Plant Sei. 66: 221 -230 (1990)) kloniert (siehe Abbildung 2). Dieser enthält den 35S-Promotor des CaMV (Blumen- kohlmosaikvirus) (Franck et al . , Cell 21: 285 - 294 (1980)) und das Terminationssignal des Octopin-Synthase Gens (Gielen et al . ,
35 EMBO J. 3: 835 - 846 ( 1984)). Dieser Vector vermittelt in Pflanzen Resistenz gegen das Antibiotikum Kanamycin. Die erhaltenen DNA Konstrukte enthielten das PCR Fragment in Sense und Antisense Orientierung. Das Antisensekonstrukt wurde zur Erzeugung transgener Pflanzen eingesetzt. 0
Abbildung 2: Fragment A (529 bp) beinhaltet den 35S-Promotor des CaMV (Nukleotide 6909 bis 7437 des Blumenkohlmosaikvirus) . Fragment B das Fragment des F3H Gens in Antisense-Orientierung. Fragment C (192 Bp) enthält das Terminationssignal des Octopin-Syn- 5 thase Gens.
Klonierung eines größeren cDNA Fragmentes der Flavanone-3-Hydro- xylase aus Lycopersicon esculentum Mill.cv. Moneymaker unter Verwendung des 5'RACESystems.
i Um auszuschließen, dass die Erzeugung von Pflanzen mit reduzierter mRNA Fließgleichgewichtsmenge der F3H aufgrund der geringen Größe des im Antisensekonstrukt verwendeten F3H PCR Fragmentes nicht erfolgreich ist, sollte ein zweites Antisense-Konstrukt unter Verwendung eines größeren F3H Fragmentes erzeugt werden.
Zum Zweck der Klonierung eines größeren Fragmentes der F3H wurde die 5'RACE Methode (System for Rapid amplification of cDNA ends) angewendet .
Verlängerung des F3H PCR Fragmentes durch die 5 'RACE-Methode unter Verwendung des 5 'RACE System for rapid amplification of cDNA ends, Version 2-0 von Life Tecgnologies™.
Aus reifen Tomatenfrüchten von Lycopersicon esculentum Mill.cv. Moneymaker wurde gesamt RNA isoliert (siehe oben) .
Die cDNA Erststrang-Synthese wurde nach Herstellerangaben unter Verwendung des GSP-1 (Gen spezifischer Primer) 5'-TTCAC- CACTGCCTGGTGGTCC-3 ' durchgeführt. Im Anschluß an einen Rnase Ver- dau, wurde die cDNA unter Anwendung des GlassMAX spin Systems von Life Tecgnologies™ gemäß den Herstellerangaben aufgereinigt.
An das 3 'Ende der gereinigten einzelsträngigen F3H cDNA wurde unter Verwendung der terminalen deoxynukleotydil-Transferase ge- maß den Herstellerangaben ein Cytosin Homopolymer addiert.
Die Amplifikation der 5' verlängerten F3H cDNA erfolgte unter Verwendung eines zweiten Gen spezifischen Primers (GSP-2) der im Bereich 3' vor der GSP-1 Erkennungsequenz bindet und somit eine , ,nested" PCR ermöglichte. Als 5 'Primer wurde der vom Hersteller gelieferte "5' RACE abrided anchor primer" verwendet, der komplementär zum homopolymeren dC-Schwanz der cDNA ist.
Das so amplifizierte und als FSHextended bezeichnete cDNA Fragment wurde nach Herstellerangaben in den Vektor pGEM-T von Promega kloniert.
Die Identität der cDNA wurde durch Sequenzierung bestätigt.
Das FSHextended cDNA Fragment wurde unter Verwendung der im Polylinker des Vektors pGEM-T vorhandenen Restriktionsschnittstellen Ncol und Pstl isoliert und die überstehenden Enden unter
Verwendung der T4-Polymerase und glatter Enden überführt. Dieses Fragment wurde in einen Smal (blunt) geschnittenen Vektor pBinAR (Höfgen und Willmitzer, 1990) kloniert (siehe Abbildung 3). Dieser enthält den 35S-Promotor des CaMV (Blumenkohlmosaikvirus) (Franck et al . , 1980) und das Terminationssignal des Octopin-Syn- thase Gens (Gielen et al., 1984). Dieser Vektor vermittelt in Pflanzen Resistenz gegen das Antibiotikum Kanamycin. Die erhaltenen DNA Konstrukte enthielten das PCR Fragment in Sense und Antisense Orientierung. Das Antisensekonstrukt wurde zur Er- zeugung transgener Pflanzen eingesetzt.
Abbildung 3: Fragment A (529 bp) beinhaltet den 35S-Promotor des CaMV (Nukleotide 6909 bis 7437 des Blumenkohlmosaikvirus) . Fragment B das Fragment des F3H Gens in Antisense-Orientierung. Frag- ment C (192 Bp) enthält das Terminationssignal des Octopin-Syn- thase Gens .
Beispiel 2
Herstellung transgener Lycopersicon esculentum Mill.cv. Moneymaker die ein Teilfragment der Flavanone-3-Hydroxylase in Antisense Orientierung exprimieren.
Es wurde die Methode nach Ling et al.. Plant Cell Report 17, 843 - 847 ( 1998 ) genutzt. Die Kultivierung erfolgt bei ca. 22°C unter einem 16 h - Licht / 8 h - Dunkel - Regime.
Tomatensamen (Lycopersicon esculentum Mill. cv. Moneymaker) wurden durch 10 minütige Inkubation in 4%iger Natriumhypochlorit - lösung inkubiert, anschließend 3 - 4 mal mit sterilem destilliertem Wasser gewaschen und auf MS Medium mit 3 % Saccharose, pH 6 , 1 zur Keimung ausgelegt. Nach einer Keimdauer von 7 - 10 d konnten die Kotyledonen für die Transformation eingesetzt werden.
Tag 1: Petrischalen mit dem Medium "MSBN" wurden mit 1,5 ml einer ca. 10 d alten Tabaksuspensionskultur überschichtet. Die Platten wurden mit Folie abgedeckt und bis zum nächsten Tag bei Raumtemperatur inkubiert.
Tag 2: Auf die mit der Tabaksuspensionskultur beschichteten Platten wurde steriles Filterpapier luftblasenfrei aufgelegt. Darauf wurden die quer geschnittenen Keimblätter mit der Oberseite nach unten aufgelegt. Die Petrischalen wurden für 3 Tage im Kulturenraum inkubiert.
Tag 5: Die Agrobakterienkultur (LBA4404) wurde durch Zentri- fugation bei ca. 3000g für 10 min sedimentiert und in MS-Mediu resuspendiert, so daß die OD 0,3 beträgt. In diese Suspension wurden die Keimblattstückchen gegeben, die unter leichtem Schüt- teln für 30 Minuten bei Raumtemperatur inkubiert wurden. Anschließend wurden die Keimblattstückchen auf sterilem Filterpapier etwas abgetrocknet und wieder zurück auf ihre Ausgangsplatten für die Fortsetzung der Cocultivierung für 3 Tage im Kulturenraum gelegt.
Tag 8: Die cocultivierten Keimblattstückchen wurden auf MSZ2K50+ß gelegt und für die nächsten 4 Wochen im Kulturenraum inkubiert. Danach erfolgte die Subkultivierung.
Sich bildende Sprosse wurden auf Wurzelinduktionsmedium gebracht.
Nach erfolgreicher Bewurzelung konnten die Pflanzen getestet und ins Gewächshaus überführt werden.
Beispiel 3
Hemmung der Cholesteri biosynthese in Kulturen primärer Rattenhe- patocyten
Herstellung der Stammlösungen
Vom Lyophilisat reifer Tomaten der Sorte "Moneymaker" enthaltend
A) allein das native Flavanon- 3 -hydroxylase Gen (Kontrolle) sowie
B) wie in Beispiel 2 beschrieben zusätzlich ein Teilfragment der Flavanon-3 -hydroxylase in Antisens Orientierung wurde eine Menge zwischen 10 und 20 mg exakt abgewogen und mit soviel DMSO versetzt, daß eine Stammlösung von 10 mM Gesamtflavonoide entstand. Von diesen Stammlösungen wurden unmittelbar vor Testbeginn Verdünnungen im Kulturmedium hergestellt. Die Verdünnungen er- folgten in 10er Schritten zwischen 10-4 und 10"8 M.
Herstellung der Hepatocytenkulturen
Primäre Hepatocyten wurden aus den Lebern von männlichen Spraque- Dawley Ratten (240-290 g) mittels Collagenase-Perfusion gewonnen (Gebhardt et al., Arzneimittel-Forschung/Drug Res. 41: 800 -804 (1991) 1990) . Die Kultivierung erfolgte in Collagen-beschichteten Petrischalen (6-well Plates, Greiner, Nürtingen) mit einer Zelldichte von 125.000 Zellen/cm2 in Williams Medium E mit 10 % Kälberserum. Nähere Angaben insbesondere zum Kulturmedium finden sich bei Gebhardt et al., Cell Biol. Toxicol. 6: 369 - 372 (1990) und Mewes et al . , Cancer Res. 53: 5135 - 5142 (1993). Die
Kulturen wurden nach 2 h auf serum-freies Medium mit Zusatz von 0,1 μM Insulin gewechselt. Sie wurden nach weiteren 20 h für die Versuche eingesetzt. Die Testsubstanzen wurden in je drei unabhängigen Kulturen von 2-3 Ratten getestet.
Inkubation der Leberzellkulturen mit den Testsubstanzen A und B
Für den Nachweis einer Beeinflussung der Cholesterin-Biosynthese durch die Testsubstanzen A und B wurden die Hepatocytenkuturen insgesamt für 22 h gehalten. Anschließend wurde mit serum-freiem Williams Medium E unter Zusatz von 14C-Acetat (nur Tracermengen) für 2 h mit den Testsubstanzen in den angegebenen Konzentrationen inkubiert. Bei jeder Testserie wurde eine Kontrolle mitgeführt. Die Methodik ist bei Gebhardt (1991) und Gebhardt, Lipids 28: 613 -619 (1993) detailliert beschrieben. Die Tracermengen von 14C-Ace- tat tauschen schnell mit dem intrazellulären Acetyl-CoA Pool aus und ermöglichen deshalb eine störungsfreie Bestimmung des Einbaus von 1C-Acetat in die Sterolfraktion, die zu >90 % aus Cholesterin besteht (Gebhardt, 1993).
Analytik zur Beeinflussung der Cholesterin-Biosynthese
Der Einbau von 1C-Acetat in die Sterolfraktion (nicht-verseifbare Lipide) wurde nach Gebhardt (1991) gemessen. Bei der verwendeten Extraktion mittels Extrelut®-Säulen (Merck, Darmstadt) wird das 14C-Acetat (und daraus in geringer Menge entstehende andere niedermolekulare Metabolite) zu mehr als 95 % abgetrennt. Dieser Test kann vergleichende Angaben über die relative Syntheserate von Cholesterin und Vorlaufer-Sterolen unter dem Einfluss von Testsubstanzen machen (Gebhardt, 1993) .
Visuelle und mikrobielle Überprüfung der Qualität der Hepatocy- tenkul uren
Alle verwendeten Kulturen wurden vor und nach der Testinkubation visuell am Mikroskop auf Kontamination mit Mikroorganismen und auf die Integrität der Zellmonolayer überprüft. Bei keiner der Proben wurde eine erkennbare Veränderung der Zellmorphologie (insbesondere bei den höheren Konzentrationen) beobachtet. Dies schließt eine Beeinflussung der Testergebnisse durch zytotoxische Wirkungen der Testsubstanzen weitgehend aus.
Die bei allen Kulturen routinemäßig durchgeführten Sterilitätstests ergaben keinerlei Hinweise auf eine Kontamination mit Mi- kroorganismen.
Ergebnisse
Proben A) aus den nicht genetisch modifizierten Tomaten (Kontrolle) zeigte keinerlei Wirkungen auf die Cholesterinbio- synthese. Dagegen wurde die Cholesterinsynthese durch Proben B aus den ein Teilfragment der Flavanon-3 -hydroxylase in Antisens- Orientierung enthaltenden Tomaten signifikant inhibiert.
Claims
1. Verfahren zur Erhöhung des Gehalts an Flavonoiden und phenolischen Inhaltsstoffen in Pflanzen dadurch gekennzeichnet, daß mit molekulargenetischen Methoden eine Pflanze hergestellt wird in der die Aktivität des Enzyms Flavanon-3-hydroxylase reduziert ist.
2. Verfahren gemäß Anspruch 1 zur Erhöhung des Gehalts an Flavonoiden und phenolischen Inhaltsstoffen in Pflanzen dadurch gekennzeichnet, daß das Enzym Flavanon-3-hydroxylase durch molekularbiologische Verfahren (z.B. Anti-Sense-Konstrukt, Co-Suppression, der Expression spezifischer Antikörper oder der Expression spezifischer Inhibitoren) ganz oder teilweise, andauernd oder vorübergehend, in der gesamten Pflanze oder in Teilen der Pflanze in seiner Aktivität reduziert ist.
3. Verfahren gemäß den Ansprüchen 1 und 2, dadurch gekennzeich- net, daß es sich bei den Pflanzen um Weinrebe, Kirsche, Tomate, Pflaume, Schlehe, Blaubeere, Erdbeere, Zitrusfrüchte
(wie Orange, Grapefruit), Papaya, Rotkohl, Broccoli, Rosenkohl, Kakao, Grünkohl, Karotte, Petersilie, Sellerie, Zwiebeln, Knoblauch, Tee, Kaffee, Hopfen, Soja, Raps, Hafer, Wei- zen, Roggen, Aronia melanocarpa, Ginkgo biloba handelt.
4. Pflanze mit erhöhtem Gehalt an Flavonoiden und phenolischen Inhaltsstoffen hergestellt nach einem Verfahren gemäß den Ansprüchen 1 - 3 dadurch gekennzeichnet, daß die enzymatische Aktivität des Enzyms Flavanon-3-hydoxylase reduziert ist.
5. Verwendung von Pflanzen oder von Teilen dieser Pflanzen hergestellt nach einem Verfahren gemäß den Ansprüchen 1 - 3 als Nahrungsmittel, Nahrungsergänzungsmittel oder zur Herstellung von heilenden, gesundheitsfördernden oder stärkenden Mitteln (Säfte, Tees, Extrakte, Fermentationsprodukte) für Mensch und Tier sowie zur Herstellung von Kosmetika.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19927574 | 1999-06-17 | ||
| DE19927574A DE19927574A1 (de) | 1999-06-17 | 1999-06-17 | Verfahren zur Herstellung von Pflanzen mit erhöhtem Gehalt an Flavonoiden und phenolischen Verbindungen |
| PCT/EP2000/005257 WO2000078980A1 (de) | 1999-06-17 | 2000-06-07 | Verfahren zur herstellung von pflanzen mit erhöhtem gehalt an flavonoiden und phenolischen verbindungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1102855A1 true EP1102855A1 (de) | 2001-05-30 |
Family
ID=7911499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP00945714A Withdrawn EP1102855A1 (de) | 1999-06-17 | 2000-06-07 | Verfahren zur herstellung von pflanzen mit erhöhtem gehalt an flavonoiden und phenolischen verbindungen |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1102855A1 (de) |
| JP (1) | JP2003503032A (de) |
| KR (1) | KR20020068256A (de) |
| CN (1) | CN1314943A (de) |
| AR (1) | AR024381A1 (de) |
| AU (1) | AU5970400A (de) |
| BG (1) | BG105246A (de) |
| BR (1) | BR0006869A (de) |
| CA (1) | CA2340319A1 (de) |
| CO (1) | CO5280139A1 (de) |
| DE (1) | DE19927574A1 (de) |
| HU (1) | HUP0103307A2 (de) |
| IL (1) | IL141173A0 (de) |
| PL (1) | PL346059A1 (de) |
| WO (1) | WO2000078980A1 (de) |
| ZA (1) | ZA200101328B (de) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100642939B1 (ko) * | 2003-02-11 | 2006-11-10 | 학교법인 신천학원 | 자두추출물을 함유하는 화장비누 및 그 추출방법 |
| JP2007520230A (ja) * | 2004-02-06 | 2007-07-26 | コンク ユニヴァーシティ インダストリアル コーペレーション コープ | 高濃度イソフラボンを含む発芽豆及びその製造方法 |
| KR100553522B1 (ko) * | 2004-02-06 | 2006-02-20 | 학교법인 건국대학교 | 이소플라본 강화 발아 녹두 및 그 제조방법 |
| KR100663669B1 (ko) * | 2005-05-18 | 2007-01-02 | 금호석유화학 주식회사 | 배유 내에 높은 농도의 플라보노이드를 생산하는 형질전환쌀 |
| WO2010123571A2 (en) * | 2009-04-21 | 2010-10-28 | Haas, John, I. | Animal feed compositions and feeding methods |
| EP2286669A1 (de) * | 2009-07-29 | 2011-02-23 | Nestec S.A. | Flavanonhaltige Lebensmittelzusammensetzungen |
| WO2013183177A1 (ja) * | 2012-06-07 | 2013-12-12 | 株式会社燦樹 | ニンニク卵黄組成物及びその製造方法 |
| KR101415687B1 (ko) * | 2012-09-19 | 2014-07-10 | 농업회사법인 호트팜 주식회사 | 조직배양기술을 이용한 아로니아의 줄기마디배양으로부터 유식물체의 대량 증식방법 |
| WO2015140589A1 (en) * | 2014-03-20 | 2015-09-24 | Hongkong Chuanghui International Limited | Method for preparation multifunctional liquid medicament from vegetable feedstock, and the product produced by the method |
| CN105985936A (zh) * | 2015-02-02 | 2016-10-05 | 中国人民解放军第二军医大学 | 灯盏花黄烷酮-3-羟化酶及其编码基因与应用 |
| CN111875689B (zh) * | 2020-08-07 | 2022-02-01 | 山东玄康种业科技有限公司 | 一种利用番茄绿茎紧密连锁标记创制雄性不育系的方法 |
| KR20230057405A (ko) | 2020-08-25 | 2023-04-28 | 오츠카 세이야쿠 가부시키가이샤 | 캠페롤 아글리콘 함유 추출물 |
| CN112391362B (zh) * | 2020-11-04 | 2022-07-05 | 江南大学 | 催化活性提高的黄酮3β-羟化酶突变体及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5432068A (en) * | 1990-06-12 | 1995-07-11 | Pioneer Hi-Bred International, Inc. | Control of male fertility using externally inducible promoter sequences |
| HUT69991A (en) * | 1992-03-09 | 1995-09-28 | Univ Washington | Methods for the regulation of plant fertility |
| GB9525459D0 (en) * | 1995-12-13 | 1996-02-14 | Zeneca Ltd | Genetic control of fruit ripening |
| AU2766099A (en) * | 1998-02-25 | 1999-09-15 | E.I. Du Pont De Nemours And Company | Plant flavanone-3-hydroxylase |
| WO2000050613A2 (en) * | 1999-02-22 | 2000-08-31 | Yissum Research And Development Company Of The Hebrew University Of Jerusalem | Transgenic plants and method for transforming carnations |
-
1999
- 1999-06-17 DE DE19927574A patent/DE19927574A1/de not_active Withdrawn
-
2000
- 2000-06-07 HU HU0103307A patent/HUP0103307A2/hu unknown
- 2000-06-07 BR BR0006869-1A patent/BR0006869A/pt not_active Application Discontinuation
- 2000-06-07 JP JP2001505720A patent/JP2003503032A/ja not_active Withdrawn
- 2000-06-07 WO PCT/EP2000/005257 patent/WO2000078980A1/de not_active Ceased
- 2000-06-07 EP EP00945714A patent/EP1102855A1/de not_active Withdrawn
- 2000-06-07 IL IL14117300A patent/IL141173A0/xx unknown
- 2000-06-07 CN CN00801147A patent/CN1314943A/zh active Pending
- 2000-06-07 AU AU59704/00A patent/AU5970400A/en not_active Abandoned
- 2000-06-07 KR KR1020017002018A patent/KR20020068256A/ko not_active Withdrawn
- 2000-06-07 CA CA002340319A patent/CA2340319A1/en not_active Abandoned
- 2000-06-07 PL PL00346059A patent/PL346059A1/xx not_active Application Discontinuation
- 2000-06-15 CO CO00044702A patent/CO5280139A1/es not_active Application Discontinuation
- 2000-06-16 AR ARP000103001A patent/AR024381A1/es unknown
-
2001
- 2001-02-13 BG BG105246A patent/BG105246A/bg unknown
- 2001-02-16 ZA ZA200101328A patent/ZA200101328B/xx unknown
Non-Patent Citations (1)
| Title |
|---|
| See references of WO0078980A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| BR0006869A (pt) | 2001-08-07 |
| ZA200101328B (en) | 2002-02-18 |
| WO2000078980A1 (de) | 2000-12-28 |
| HUP0103307A2 (hu) | 2001-12-28 |
| CO5280139A1 (es) | 2003-05-30 |
| IL141173A0 (en) | 2002-02-10 |
| PL346059A1 (en) | 2002-01-14 |
| CA2340319A1 (en) | 2000-12-28 |
| KR20020068256A (ko) | 2002-08-27 |
| DE19927574A1 (de) | 2000-12-21 |
| BG105246A (bg) | 2001-10-31 |
| CN1314943A (zh) | 2001-09-26 |
| AU5970400A (en) | 2001-01-09 |
| JP2003503032A (ja) | 2003-01-28 |
| AR024381A1 (es) | 2002-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Singh | Enhancing phytochemical levels, enzymatic and antioxidant activity of spinach leaves by chitosan treatment and an insight into the metabolic pathway using DART-MS technique | |
| Guodong et al. | Identification of putative genes for polyphenol biosynthesis in olive fruits and leaves using full-length transcriptome sequencing | |
| Deng et al. | Biosynthesis and regulation of phenylpropanoids in plants | |
| Sternad Lemut et al. | Use of metabolic profiling to study grape skin polyphenol behavior as a result of canopy microclimate manipulation in a ‘Pinot noir’vineyard | |
| Karppinen et al. | Changes in the abscisic acid levels and related gene expression during fruit development and ripening in bilberry (Vaccinium myrtillus L.) | |
| Carvalho et al. | Effect of photoperiod on flavonoid pathway activity in sweet potato (Ipomoea batatas (L.) Lam.) leaves | |
| Kim et al. | Analysis of eight phytohormone concentrations, expression levels of ABA biosynthesis genes, and ripening-related transcription factors during fruit development in strawberry | |
| Gruz et al. | Phenolic acid content and radical scavenging activity of extracts from medlar (Mespilus germanica L.) fruit at different stages of ripening | |
| EP1185175B1 (de) | Verfahren zur erhöhung vom gehalt an flavonoiden und phenolischen inhaltsstoffen in pflanzen | |
| Yang et al. | Effects of latitude and weather conditions on phenolic compounds in currant (Ribes spp.) cultivars | |
| Gagné et al. | Leucoanthocyanidin reductase and anthocyanidin reductase gene expression and activity in flowers, young berries and skins of Vitis vinifera L. cv. Cabernet-Sauvignon during development | |
| Wang et al. | Resveratrol synthesis under natural conditions and after UV-C irradiation in berry skin is associated with berry development stages in ‘Beihong’(V. vinifera× V. amurensis) | |
| EP1102855A1 (de) | Verfahren zur herstellung von pflanzen mit erhöhtem gehalt an flavonoiden und phenolischen verbindungen | |
| Moyo et al. | Plant regeneration and biochemical accumulation of hydroxybenzoic and hydroxycinnamic acid derivatives in Hypoxis hemerocallidea organ and callus cultures | |
| Kianersi et al. | Biosynthesis of rutin changes in Capparis spinosa due to altered expression of its pathway genes under elicitors’ supplementation | |
| Li et al. | Accumulation of flavonoids and expression of flavonoid biosynthetic genes in tartary and rice-tartary buckwheat | |
| Chen et al. | Pigments in citrus | |
| Kambiranda et al. | In depth proteome analysis of ripening muscadine grape berry cv. carlos reveals proteins associated with flavor and aroma compounds | |
| Grujić et al. | Glandular trichomes, essential oil composition, anti-Aspergillus and antioxidative activities of Lamium purpureum L. ethanolic extracts | |
| Hata et al. | Effect of photoperiod on growth of the plants, and sesamin content and CYP81Q1 gene expression in the leaves of sesame (Sesamum indicum L.) | |
| Davy et al. | Extraction and formulation of valuable components from banana peels | |
| EP4426119A1 (de) | Zusammensetzung zur verwendung in pflanzen und verwendungen davon | |
| Vargas et al. | Biotechnological potential of hairy roots from an argentine peanut (Arachis hypogaea L.) type runner cultivar granoleico | |
| Müller | Physiological and phytochemical aspects of ant-plant mutualism | |
| Liu et al. | Changes in the expression of genes related to the biosynthesis of catechins in tea (Camellia sinensis L.) under greenhouse conditions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20010206 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT |
|
| AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO PAYMENT 20010206;SI |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20030103 |